Project/Area Number |
08670902
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Pediatrics
|
Research Institution | YOKOHAMA CITY UNIVERSITY |
Principal Investigator |
IKUTA Koichiro Yokohama City Univ., School of Med., Assistant Professor, 医学部, 講師 (80159590)
|
Co-Investigator(Kenkyū-buntansha) |
FUNABIKI Tetsunori Yokohama City Univ., School of Med., Instructor, 医学部, 助手 (20264616)
SASAKI Hideki Yokohama City Univ., School of Med., Associate Professor, 医学部, 助教授 (50106316)
|
Project Period (FY) |
1996 – 1997
|
Project Status |
Completed (Fiscal Year 1997)
|
Budget Amount *help |
¥2,200,000 (Direct Cost: ¥2,200,000)
Fiscal Year 1997: ¥1,100,000 (Direct Cost: ¥1,100,000)
Fiscal Year 1996: ¥1,100,000 (Direct Cost: ¥1,100,000)
|
Keywords | acute leukemia / PBSCT / PBSC / MRD / IgH / TCR / RT-PCR / chimeric RNA / 自家末梢血幹細胞移植 / 微少残存白血病 / 遺伝子再構成 / ALL / AML |
Research Abstract |
We investigated minimal residual disease (MRD) in autologous peripheral blood stem cell transplantation (PBSCT) for acute lymphoblastic leukemia (ALL) and acute myeloblastic leukemia (AML) in children. MRD can be defined as disease occurring at a subclinical level and beyond detection by conventional methods of assessment. Application of the polymerase chain reaction (PCR) to the hypervariable segment of the immunoglobulin heavy chain (IgH) gene or T-lymphocyte receptor gene and RT-PCR of specific chimera messenger RNA,allows detection of MRD in ALL and AML at a level of one leukemic cell in 10^4-10^5 normal marrow cells. The detection of MRD of harvested peripheral blood stem cell (PBSC) have a value in the indication of autologous PBSCT.We detected MRD in the harvested PBSC after complete remission for 3 cases of ALL and 4 cases of AML.In a case of AML with t(8 ; 21)(q22 ; q22), chimeric RNA was detected in PBSC.In other cases, MRD was not detected in PBSC.These 7 patients with acute leukemia were performed autologous PBSCT.Six patients have sustained complete remission without sign of MRD after transplantation. But in a case of AML with t(8 ; 21)(q22 ; q22) who has chimeric RNA in her PBSC,bone marrow relapse occurred 6 month after transplantation.
|